References
- Sakata VM, da Silva FT, Hirata CE, de Carvalho JF, Yamamoto JH. Diagnosis and classification of Vogt–Koyanagi–Harada disease. Autoimmun Rev. 2014;13(4–5):550–5.
- Andreoli MC, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46(2):111–22.
- Zmuda M, Tiev KP, Knoeri J, Héron E. Successful use of infliximab therapy in sightthreatening corticosteroid-resistant Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2013;21(4):310–6.
- Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA. Management of Pediatric Vogt-Koyanagi- Harada (VKH)-Associated Panuveitis. Ocul Immunol Inflamm. 2006;14(2):91–8.
- Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev. 2010;9(12):801–3.
- Tappeiner C, Heinz C, Specker C. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res. 2007;39(3):184–6.
- Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt–Koyanagi–Harada disease. J Ophthalmic Inflamm Infect. 2011;1(4):177–80.
- Tugal-Tutkun I, Ozyazgan Y, Akova YA, Sullu Y, Akyol N, Soylu M, Kazokoglu H. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol. 2007;27(2–3):117–23.
- Khalifa YM, Bailony MR, Acharya NR. Treatment of Pediatric Vogt-Koyanagi-Harada Syndrome with Infliximab. Ocul Immunol Inflamm. 2010;18(3):218–22.
- Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146(6):837–44.
- Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481–6.
- Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS. 2008;12(6):611–3.
- Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11(1):35–9.
- Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(8):1390–4.
- Caso F, Rigante D, Vitale A, Costa L, Bascherini V, Latronico E, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2014. [Epub ahead of print]